Alemtuzumab Injection (Chronic Lymphocytic Leukemia)

Generic name: Pronounced as (al'' em tooz' oo mab)
Brand names
  • Campath®
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 08/15/2020

Alemtuzumab injection (Campath) is only available though a special restricted distribution program (Campath Distribution Program). In order to receive alemtuzumab injection (Campath) your doctor must be registered with the program, and follow the requirements. The Campath Distribution Program will ship the medication directly to the doctor, hospital, or pharmacy.

Alemtuzumab injection may cause a decrease in the number of blood cells made by your bone marrow. If you experience any of the following symptoms, call your doctor immediately: unusual bruising or bleeding, small reddish or purple blood spots on your body, pale skin, weakness, or excessive tiredness. You will need to take extra precautions to avoid injury during your treatment because you may bleed heavily from minor cuts or scrapes. Brush your teeth with a soft toothbrush, use an electric razor if you shave, and avoid contact sports and other activities that may cause injury.

Alemtuzumab injection may decrease your ability to fight infection and increase the risk that you will get a serious or life threatening infection. Call your doctor immediately if you develop any signs of infection such as fever, cough, sore throat, or a wound that is red, oozing pus, or slow to heal.

You will need to take precautions to decrease the risk of infection during your treatment with alemtuzumab injection. Your doctor will prescribe certain medications to prevent infection. You will take these medications during your treatment and for at least 2 months after your treatment. Take these medications exactly as directed. You should also wash your hands often and avoid people who have contagious infections such as coughs and colds. If you need any type of blood transfusion during your treatment with alemtuzumab injection, you should receive only irradiated blood products (blood products that have been treated to prevent a certain serious reaction that may occur in people who have weakened immune systems).

You may experience a serious or fatal reaction while you receive a dose of alemtuzumab injection. You will receive each dose of medication in a medical facility, and your doctor will monitor you carefully while you are receiving the medication. Your doctor will prescribe certain medications to prevent these reactions. You will take these medications shortly before you receive each dose of alemtuzumab. Your doctor will start you on a low dose of alemtuzumab and gradually increase your dose to allow your body to adjust to the medication. If you experience any of the following symptoms during or after your infusion, tell your doctor immediately: fever; chills; nausea; vomiting; hives; rash; itching; difficulty breathing or swallowing; slowed breathing; tightening of the throat; swelling of the eyes, face, mouth, lips, tongue or throat; hoarseness; dizziness; lightheadedness; fainting; fast or irregular heartbeat; or chest pain.

Keep all appointments with your doctor and the laboratory. Your doctor will order certain tests during and after your treatment to check your body's response to alemtuzumab injection.

Talk to your doctor about the risks of receiving alemtuzumab injection.

Alemtuzumab injection is used to treat B-cell chronic lymphocytic leukemia (B-CLL; a slowly developing cancer in which too many of a certain type of white blood cell accumulate in the body). Alemtuzumab is in a class of medications called monoclonal antibodies. It works by activating the immune system to destroy cancer cells.

Alemtuzumab is also available as an injection (Lemtrada) that is used to treat multiple sclerosis (a disease in which the nerves do not function properly; you may experience weakness, numbness, loss of muscle coordination and problems with vision, speech, and bladder control). This monograph only gives information about alemtuzumab injection (Campath) for B-CLL. If you are receiving alemtuzumab for multiple sclerosis, read the monograph entitled Alemtuzumab Injection (Multiple Sclerosis).

Alemtuzumab injection comes as a solution (liquid) to be injected intravenously (into a vein) over at least 2 hours by a doctor or nurse in a hospital or medical office. At first, alemtuzumab injection is usually given in gradually increasing doses for 3 to 7 days to allow the body to adjust to the medication. Once the body has adjusted to the needed dose of alemtuzumab injection, the medication is usually given three times weekly on alternate days (usually Monday, Wednesday, and Friday) for up to 12 weeks.

The medications you receive before each dose of alemtuzumab injection might make you sleepy. You will probably want to ask a family member or friend to come with you when you receive your medication and to take you home afterward.

Although your condition may improve as soon as 4 to 6 weeks after you begin treatment with alemtuzumab injection, your treatment will probably last for 12 weeks. Your doctor will decide whether to continue your treatment and may adjust your dose depending on how well the medication works for you and on the side effects you experience.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Before receiving alemtuzumab injection,

  • tell your doctor and pharmacist if you are allergic to alemtuzumab injection or any other medications.

  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take.

  • tell your doctor if you have or have ever had any medical conditions.

  • tell your doctor if you or your partner are pregnant or plan to become pregnant. You will have to take a pregnancy test before starting treatment and use birth control to prevent pregnancy during your treatment and for 3 months after your final dose. If you become pregnant during your treatment with alemtuzumab injection, call your doctor immediately. Alemtuzumab may harm the fetus.

  • tell your doctor if you are breastfeeding. Do not breastfeed during treatment with alemtuzumab and for 3 months after the final dose.

  • do not have any live vaccinations during or shortly after your treatment with alemtuzumab injection without talking to your doctor. Women receiving alemtuzumab injection while pregnant should talk to their pediatrician as their infant may not be able to receive live vaccines for a certain period of time.

  • you should know that this medication may decrease fertility in men and women. Talk to your doctor about the risks of receiving alemtuzumab.

  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are receiving alemtuzumab injection.

Unless your doctor tells you otherwise, continue your normal diet.

  • Alemtuzumab injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • nausea

    • vomiting

    • stomach pain

    • diarrhea

    • loss of appetite

    • mouth sores

    • headache

    • anxiety

    • difficulty falling asleep or staying asleep

    • uncontrollable shaking of a part of the body

    • muscle pain

  • Some side effects can be serious. If you experience any of these symptoms or those listed in the IMPORTANT WARNING section, call your doctor immediately or get emergency medical treatment:

    • drooping on one side of the face; sudden weakness or numbness of an arm or leg, especially on one side of the body; or difficulty speaking or understanding

    • swelling in legs and ankles, weight gain, fatigue. or foamy urine (may occur months or years after your final dose)

  • Alemtuzumab may cause other side effects. Call your doctor if you have any unusual problems while receiving this medication.

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Symptoms of overdose may include the following:

  • tightening of the throat

  • difficulty breathing

  • cough

  • decreased urination

  • unusual bruising or bleeding

  • reddish or purple spots on the skin

  • pale skin

  • weakness

  • excessive tiredness

  • sore throat, fever, chills, and other signs of infection

  • nausea

  • vomiting

  • hives

  • rash

  • itching

  • swelling of the eyes, face, mouth, throat, lips, or tongue

  • fast or irregular heartbeat

  • fainting

  • chest pain

Ask your pharmacist any questions you have about alemtuzumab injection.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug Interaction
Leflunomide Leflunomide The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Leflunomide.
Anagrelide Anagrelide The risk or severity of bleeding can be increased when Anagrelide is combined with Alemtuzumab.
Cilostazol Cilostazol The risk or severity of bleeding can be increased when Cilostazol is combined with Alemtuzumab.
Clopidogrel Clopidogrel The risk or severity of bleeding can be increased when Clopidogrel is combined with Alemtuzumab.
Estrogen and Progestin (Oral Contraceptives) Estrogen and Progestin (Oral Contraceptives) Conjugated estrogens may increase the thrombogenic activities of Alemtuzumab.
Mycophenolate Mycophenolate The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mycophenolic acid.
Prednisone Prednisone The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Prednisone.
Tacrolimus Tacrolimus Tacrolimus may increase the immunosuppressive activities of Alemtuzumab.
Triamcinolone Triamcinolone The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Triamcinolone.
Interferon Beta-1b Injection Interferon Beta-1b Injection The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Alemtuzumab.
Interferon Gamma-1b Injection Interferon Gamma-1b Injection The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Alemtuzumab.
Methylprednisolone Injection Methylprednisolone Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Methylprednisolone.
Zidovudine Injection Zidovudine Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Zidovudine.
Cyclosporine Cyclosporine Alemtuzumab may increase the immunosuppressive activities of Cyclosporine.
Enoxaparin Injection Enoxaparin Injection The risk or severity of bleeding can be increased when Enoxaparin is combined with Alemtuzumab.
Hydroxychloroquine Hydroxychloroquine The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hydroxychloroquine.
Temozolomide Temozolomide The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Temozolomide.
Anakinra Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Alemtuzumab.
Linezolid Linezolid The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Linezolid.
Pentosan Polysulfate Pentosan Polysulfate The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Alemtuzumab.
Etanercept Injection Etanercept Injection The risk or severity of adverse effects can be increased when Etanercept is combined with Alemtuzumab.
Sirolimus Sirolimus The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sirolimus.
Epirubicin Epirubicin The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Epirubicin.
Adalimumab Injection Adalimumab Injection The risk or severity of adverse effects can be increased when Adalimumab is combined with Alemtuzumab.
Glatiramer Injection Glatiramer Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Glatiramer.
Omalizumab Injection Omalizumab Injection The risk or severity of adverse effects can be increased when Omalizumab is combined with Alemtuzumab.
Darbepoetin Alfa Injection Darbepoetin Alfa Injection The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Alemtuzumab.
Infliximab Injection Infliximab Injection The risk or severity of adverse effects can be increased when Infliximab is combined with Alemtuzumab.
Natalizumab Injection Natalizumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Natalizumab.
Palifermin Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Alemtuzumab.
Peginterferon Alfa-2a Injection Peginterferon Alfa-2a Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Alemtuzumab.
Peginterferon Alfa-2b (PEG-Intron) Peginterferon Alfa-2b (PEG-Intron) The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Alemtuzumab.
Abatacept Injection Abatacept Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Abatacept.
Imatinib Imatinib The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Imatinib.
Bevacizumab Injection Bevacizumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bevacizumab.
Bortezomib Bortezomib The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bortezomib.
Clofarabine Injection Clofarabine Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Clofarabine.
Hepatitis B Vaccine Hepatitis B Vaccine The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Alemtuzumab.
Influenza Vaccine, Inactivated or Recombinant Influenza Vaccine, Inactivated or Recombinant The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.
Influenza Vaccine, Live Intranasal Influenza Vaccine, Live Intranasal The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Alemtuzumab.
Live Shingles (Zoster) Vaccine (ZVL) Live Shingles (Zoster) Vaccine (ZVL) The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Alemtuzumab.
Oxaliplatin Injection Oxaliplatin Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Oxaliplatin.
Rituximab Injection Rituximab Injection The risk or severity of adverse effects can be increased when Rituximab is combined with Alemtuzumab.
Cetuximab Injection Cetuximab Injection The risk or severity of adverse effects can be increased when Cetuximab is combined with Alemtuzumab.
Pemetrexed Injection Pemetrexed Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pemetrexed.
Ranibizumab Injection Ranibizumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ranibizumab.
Vorinostat Vorinostat The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vorinostat.
Sorafenib Sorafenib The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sorafenib.
Sunitinib Sunitinib The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sunitinib.
Dasatinib Dasatinib The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dasatinib.
Panitumumab Injection Panitumumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Panitumumab.
Azacitidine Injection Azacitidine Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Azacitidine.
Temsirolimus Temsirolimus The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Temsirolimus.
Nelarabine Injection Nelarabine Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Nelarabine.
Lenalidomide Lenalidomide The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lenalidomide.
Nilotinib Nilotinib The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Nilotinib.
Bexarotene Bexarotene The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bexarotene.
Budesonide Budesonide The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Budesonide.
Chloramphenicol Injection Chloramphenicol Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Chloramphenicol.
Decitabine Injection Decitabine Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Decitabine.
Arsenic Trioxide Injection Arsenic Trioxide Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Arsenic trioxide.
Mitoxantrone Injection Mitoxantrone Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mitoxantrone.
Tretinoin Tretinoin The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tretinoin.
Bendamustine Injection Bendamustine Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bendamustine.
Certolizumab Injection Certolizumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Certolizumab pegol.
Ixabepilone Injection Ixabepilone Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ixabepilone.
Irinotecan Injection Irinotecan Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Irinotecan.
Estramustine Estramustine The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Estramustine.
Dexrazoxane Injection Dexrazoxane Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dexrazoxane.
Ibritumomab Injection Ibritumomab Injection The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Alemtuzumab.
Prasugrel Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Alemtuzumab.
Everolimus Everolimus The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Everolimus.
Pralatrexate Injection Pralatrexate Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pralatrexate.
Topotecan Topotecan The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Topotecan.
Ofatumumab Injection (Chronic Lymphocytic Leukemia) Ofatumumab Injection (Chronic Lymphocytic Leukemia) The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ofatumumab.
Golimumab Injection Golimumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Golimumab.
Pazopanib Pazopanib The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pazopanib.
Denosumab Injection Denosumab Injection The risk or severity of adverse effects can be increased when Denosumab is combined with Alemtuzumab.
Dabigatran Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Alemtuzumab.
Tocilizumab Injection Tocilizumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tocilizumab.
Fingolimod Fingolimod Alemtuzumab may increase the immunosuppressive activities of Fingolimod.
Eribulin Injection Eribulin Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eribulin.
Cabazitaxel Injection Cabazitaxel Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cabazitaxel.
Ustekinumab Injection Ustekinumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ustekinumab.
Ipilimumab Injection Ipilimumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ipilimumab.
Denileukin Diftitox Injection Denileukin Diftitox Injection The risk or severity of adverse effects can be increased when Aldesleukin is combined with Alemtuzumab.
Sipuleucel-T Injection Sipuleucel-T Injection The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Alemtuzumab.
Belimumab Injection Belimumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Belimumab.
Busulfan Injection Busulfan Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Busulfan.
Roflumilast Roflumilast Roflumilast may increase the immunosuppressive activities of Alemtuzumab.
Cyclophosphamide Injection Cyclophosphamide Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cyclophosphamide.
Rivaroxaban Rivaroxaban The risk or severity of bleeding can be increased when Rivaroxaban is combined with Alemtuzumab.
Ticagrelor Ticagrelor The risk or severity of bleeding can be increased when Ticagrelor is combined with Alemtuzumab.
Brentuximab Vedotin Injection Brentuximab Vedotin Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Brentuximab vedotin.
Ruxolitinib Ruxolitinib The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ruxolitinib.
Belatacept Injection Belatacept Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Belatacept.
Basiliximab Injection Basiliximab Injection The risk or severity of adverse effects can be increased when Basiliximab is combined with Alemtuzumab.
Melphalan Injection Melphalan Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Melphalan.
Eculizumab Injection Eculizumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eculizumab.
Fondaparinux Injection Fondaparinux Injection The risk or severity of bleeding can be increased when Fondaparinux is combined with Alemtuzumab.
Pertuzumab Injection Pertuzumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pertuzumab.
Carfilzomib Injection Carfilzomib Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carfilzomib.
Iloprost Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Alemtuzumab.
Bosutinib Bosutinib The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bosutinib.
Corticotropin, Repository Injection Corticotropin, Repository Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Corticotropin.
Teriflunomide Teriflunomide The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Teriflunomide.
Icosapent Ethyl Icosapent Ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Alemtuzumab.
Tofacitinib Tofacitinib Alemtuzumab may increase the immunosuppressive activities of Tofacitinib.
Dimethyl Fumarate Dimethyl Fumarate The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dimethyl fumarate.
Ponatinib Ponatinib The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ponatinib.
Pomalidomide Pomalidomide The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pomalidomide.
Ado-trastuzumab Emtansine Injection Ado-trastuzumab Emtansine Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Trastuzumab emtansine.
Apixaban Apixaban The risk or severity of bleeding can be increased when Apixaban is combined with Alemtuzumab.
Ibrutinib Ibrutinib The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ibrutinib.
Obinutuzumab Injection Obinutuzumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Obinutuzumab.
Apremilast Apremilast The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Apremilast.
Ramucirumab Injection Ramucirumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ramucirumab.
Siltuximab Injection Siltuximab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Siltuximab.
Vedolizumab Injection Vedolizumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vedolizumab.
Belinostat Injection Belinostat Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Belinostat.
Idelalisib Idelalisib The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Idelalisib.
Vorapaxar Vorapaxar The risk or severity of bleeding can be increased when Vorapaxar is combined with Alemtuzumab.
Dulaglutide Injection Dulaglutide Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dulaglutide.
Pembrolizumab Injection Pembrolizumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pembrolizumab.
Edoxaban Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Alemtuzumab.
Nivolumab Injection Nivolumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Nivolumab.
Peginterferon Beta-1a Injection Peginterferon Beta-1a Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Peginterferon beta-1a.
Olaparib Olaparib The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Olaparib.
Blinatumomab Injection Blinatumomab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Blinatumomab.
Pirfenidone Pirfenidone The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pirfenidone.
Secukinumab Injection Secukinumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Secukinumab.
Palbociclib Palbociclib The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Palbociclib.
Panobinostat Panobinostat The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Panobinostat.
Dinutuximab Injection Dinutuximab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dinutuximab.
Alirocumab Injection Alirocumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Alirocumab.
Prednisolone Prednisolone The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Prednisolone.
Evolocumab Injection Evolocumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Evolocumab.
Mepolizumab Injection Mepolizumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mepolizumab.
Trabectedin Injection Trabectedin Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Trabectedin.
Elotuzumab Injection Elotuzumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Elotuzumab.
Daratumumab Injection Daratumumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Daratumumab.
Necitumumab Injection Necitumumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Necitumumab.
Dexamethasone Injection Dexamethasone Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dexamethasone.
Reslizumab Injection Reslizumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Reslizumab.
Defibrotide Injection Defibrotide Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Alemtuzumab.
Ixekizumab Injection Ixekizumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ixekizumab.
Atezolizumab Injection Atezolizumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Atezolizumab.
Olaratumab Injection Olaratumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Olaratumab.
Bezlotoxumab Injection Bezlotoxumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bezlotoxumab.
Avelumab Injection Avelumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Avelumab.
Brodalumab Injection Brodalumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Brodalumab.
Dupilumab Injection Dupilumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dupilumab.
Deflazacort Deflazacort The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Deflazacort.
Ocrelizumab Injection Ocrelizumab Injection Ocrelizumab may increase the immunosuppressive activities of Alemtuzumab.
Durvalumab Injection Durvalumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Durvalumab.
Sarilumab Injection Sarilumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sarilumab.
Guselkumab Injection Guselkumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Guselkumab.
Inotuzumab Ozogamicin Injection Inotuzumab Ozogamicin Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Inotuzumab ozogamicin.
Betrixaban Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Alemtuzumab.
Benralizumab Injection Benralizumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Benralizumab.
Gemtuzumab Ozogamicin Injection Gemtuzumab Ozogamicin Injection The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Alemtuzumab.
Ibalizumab-uiyk Injection Ibalizumab-uiyk Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ibalizumab.
Penicillamine Penicillamine The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Penicillamine.
Tildrakizumab-asmn injection Tildrakizumab-asmn injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tildrakizumab.
Erenumab-aooe Injection Erenumab-aooe Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Erenumab.
Baricitinib Baricitinib The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Baricitinib.
Burosumab-twza Injection Burosumab-twza Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Burosumab.
Cemiplimab-rwlc Injection Cemiplimab-rwlc Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cemiplimab.
Galcanezumab-gnlm Injection Galcanezumab-gnlm Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Galcanezumab.
Mogamulizumab-kpkc Injection Mogamulizumab-kpkc Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mogamulizumab.
Methoxy Polyethylene Glycol-Epoetin Beta Injection Methoxy Polyethylene Glycol-Epoetin Beta Injection The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Alemtuzumab.
Paclitaxel (with albumin) Injection Paclitaxel (with albumin) Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Paclitaxel.
Ravulizumab-cwvz Injection Ravulizumab-cwvz Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ravulizumab.
Emapalumab-lzsg Injection Emapalumab-lzsg Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Emapalumab.
Romosozumab-aqqg Injection Romosozumab-aqqg Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Romosozumab.
Siponimod Siponimod The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Siponimod.
Caplacizumab-yhdp Injection Caplacizumab-yhdp Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Caplacizumab.
Risankizumab-rzaa Injection Risankizumab-rzaa Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Risankizumab.
Cladribine Cladribine The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cladribine.
Polatuzumab vedotin-piiq Injection Polatuzumab vedotin-piiq Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Polatuzumab vedotin.
Brolucizumab-dbll Injection Brolucizumab-dbll Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Brolucizumab.
Fam-trastuzumab deruxtecan-nxki Injection Fam-trastuzumab deruxtecan-nxki Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Trastuzumab deruxtecan.
Isatuximab-irfc Injection Isatuximab-irfc Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Isatuximab.
Teprotumumab-trbw Injection Teprotumumab-trbw Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Teprotumumab.
Ozanimod Ozanimod The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ozanimod.
Sacituzumab govitecan-hziy Injection Sacituzumab govitecan-hziy Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sacituzumab govitecan.
Luspatercept-aamt Injection Luspatercept-aamt Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Luspatercept.
Belantamab Mafodotin-blmf Injection Belantamab Mafodotin-blmf Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Belantamab mafodotin.
Tafasitamab-cxix Injection Tafasitamab-cxix Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tafasitamab.
Margetuximab-cmkb Injection Margetuximab-cmkb Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Margetuximab.
Evinacumab-dgnb Injection Evinacumab-dgnb Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Evinacumab.
Aducanumab-avwa Injection Aducanumab-avwa Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Aducanumab.
Anifrolumab-fnia Injection Anifrolumab-fnia Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Anifrolumab.
Indomethacin Indomethacin The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Indomethacin.
Hydroxyurea Hydroxyurea The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hydroxyurea.
Floxuridine Floxuridine The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Floxuridine.
Methotrexate Injection Methotrexate Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Methotrexate.
Carmustine Carmustine The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carmustine.
Procarbazine Procarbazine The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Procarbazine.
Thioguanine Thioguanine The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tioguanine.
Bleomycin Bleomycin The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bleomycin.
Azathioprine Azathioprine The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Azathioprine.
Sulfasalazine Sulfasalazine The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sulfasalazine.
Lomustine Lomustine The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lomustine.
Doxorubicin Doxorubicin The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Doxorubicin.
Cytarabine Cytarabine The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cytarabine.
Mechlorethamine Mechlorethamine The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mechlorethamine.
Dactinomycin Dactinomycin The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dactinomycin.
Carbamazepine Carbamazepine The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carbamazepine.
Warfarin Warfarin The risk or severity of bleeding can be increased when Warfarin is combined with Alemtuzumab.
Daunorubicin Daunorubicin The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Daunorubicin.
Sulfinpyrazone Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Alemtuzumab.
Chlorothiazide Chlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Alemtuzumab.
Mitomycin Mitomycin The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mitomycin.
Methimazole Methimazole The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Methimazole.
Propylthiouracil Propylthiouracil The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Propylthiouracil.
Methyclothiazide Methyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Alemtuzumab.
Hydrochlorothiazide Hydrochlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Alemtuzumab.
Mercaptopurine Mercaptopurine The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mercaptopurine.
Allopurinol Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Alemtuzumab.
Fluorouracil Injection Fluorouracil Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluorouracil.
Colchicine Colchicine The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Colchicine.
Dacarbazine Dacarbazine The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dacarbazine.
Bacillus Calmette-Guerin (BCG) Vaccine Bacillus Calmette-Guerin (BCG) Vaccine The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Alemtuzumab.
Thiotepa Injection Thiotepa Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Thiotepa.
Vincristine Injection Vincristine Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vincristine.
Dipyridamole Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Alemtuzumab.
Vinblastine Vinblastine The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vinblastine.
Aspirin Aspirin The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Alemtuzumab.
Chlorambucil Chlorambucil The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Chlorambucil.
Cisplatin Injection Cisplatin Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cisplatin.
Streptozocin Streptozocin The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Streptozocin.
Etoposide Etoposide The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Etoposide.
Pentoxifylline Pentoxifylline The risk or severity of bleeding can be increased when Pentoxifylline is combined with Alemtuzumab.
Interferon Alfa-2b Injection Interferon Alfa-2b Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Interferon alfa-2b.
Clozapine Clozapine The risk or severity of neutropenia can be increased when Alemtuzumab is combined with Clozapine.
Idarubicin Idarubicin The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Idarubicin.
Fludarabine Injection Fludarabine Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fludarabine.
Pentostatin Injection Pentostatin Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pentostatin.
Epoetin Alfa, Injection Epoetin Alfa, Injection The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Alemtuzumab.
Teniposide Injection Teniposide Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Teniposide.
Vinorelbine Injection Vinorelbine Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vinorelbine.
Carboplatin Injection Carboplatin Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carboplatin.
Ifosfamide Injection Ifosfamide Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ifosfamide.
Pegaspargase Injection Pegaspargase Injection The risk or severity of adverse effects can be increased when Pegaspargase is combined with Alemtuzumab.
Ticlopidine Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Alemtuzumab.
Dalteparin Injection Dalteparin Injection The risk or severity of bleeding can be increased when Dalteparin is combined with Alemtuzumab.
Gemcitabine Injection Gemcitabine Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gemcitabine.
Docetaxel Injection Docetaxel Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Docetaxel.
Palivizumab Injection Palivizumab Injection The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Palivizumab.
Capecitabine Capecitabine The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Capecitabine.
Trastuzumab Injection Trastuzumab Injection Trastuzumab may increase the neutropenic activities of Alemtuzumab.
Thalidomide Thalidomide The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Thalidomide.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists